Sam Agresta

5.2k total citations
27 papers, 912 citations indexed

About

Sam Agresta is a scholar working on Hematology, Cancer Research and Molecular Biology. According to data from OpenAlex, Sam Agresta has authored 27 papers receiving a total of 912 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 12 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in Sam Agresta's work include Acute Myeloid Leukemia Research (14 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Cancer Genomics and Diagnostics (8 papers). Sam Agresta is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Cancer Genomics and Diagnostics (8 papers). Sam Agresta collaborates with scholars based in United States, France and Ireland. Sam Agresta's co-authors include Katharine Yen, Hua Yang, Camelia Gliser, Courtney D. DiNardo, Hagop M. Kantarjian, Mark J. Routbort, Tapan M. Kadia, Guillermo Garcia‐Manero, Jörge E. Cortes and Keyur P. Patel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Sam Agresta

27 papers receiving 903 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sam Agresta United States	15	474	442	315	285	127	27	912
Kathy L. McGraw United States	18	558 1.2×	756 1.7×	125 0.4×	343 1.2×	86 0.7×	53	1.2k
Ashwin Kishtagari United States	11	305 0.6×	564 1.3×	221 0.7×	323 1.1×	60 0.5×	56	857
Gabriella Sammarelli Italy	16	404 0.9×	465 1.1×	109 0.3×	193 0.7×	174 1.4×	39	938
Zineb Hamilou Canada	6	265 0.6×	408 0.9×	134 0.4×	238 0.8×	44 0.3×	18	652
Marie Jarošová Czechia	17	264 0.6×	354 0.8×	88 0.3×	301 1.1×	95 0.7×	87	766
Jakob Werner Hansen Denmark	13	216 0.5×	218 0.5×	153 0.5×	260 0.9×	88 0.7×	39	822
Katherine Waghorn United Kingdom	10	730 1.5×	660 1.5×	115 0.4×	500 1.8×	75 0.6×	13	1.2k
Annette Fasan Germany	14	646 1.4×	676 1.5×	258 0.8×	299 1.0×	188 1.5×	34	1.2k
Stéphanie Struski France	16	264 0.6×	171 0.4×	84 0.3×	134 0.5×	76 0.6×	30	596
Carrie Brownstein United States	12	346 0.7×	174 0.4×	159 0.5×	169 0.6×	95 0.7×	32	699

Countries citing papers authored by Sam Agresta

Since Specialization

Citations

This map shows the geographic impact of Sam Agresta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sam Agresta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sam Agresta more than expected).

Fields of papers citing papers by Sam Agresta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sam Agresta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sam Agresta. The network helps show where Sam Agresta may publish in the future.

Co-authorship network of co-authors of Sam Agresta

This figure shows the co-authorship network connecting the top 25 collaborators of Sam Agresta. A scholar is included among the top collaborators of Sam Agresta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sam Agresta. Sam Agresta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Collins, Mike, Gabriel J. Sandoval, Ammar Adam, et al.. (2023). Abstract 2122: The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of AML. Cancer Research. 83(7_Supplement). 2122–2122. 2 indexed citations

Prakash, Chandra, et al.. (2019). Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. Cancer Chemotherapy and Pharmacology. 83(5). 837–848. 14 indexed citations

Fan, Bin, Ingo K. Mellinghoff, Patrick Y. Wen, et al.. (2019). Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational New Drugs. 38(2). 433–444. 71 indexed citations

Yang, Hua, Yue Chen, Marvin B. Cohen, et al.. (2018). Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers. Clinical Pharmacology in Drug Development. 8(2). 246–259. 39 indexed citations

Mellinghoff, Ingo K., Mehdi Touat, Elizabeth A. Maher, et al.. (2016). ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS. Neuro-Oncology. 18(suppl_6). vi12–vi12. 15 indexed citations

Gao, Yue, Bin Fan, Kha Le, et al.. (2015). Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial. Blood. 126(23). 2509–2509. 5 indexed citations

DiNardo, Courtney D., Stéphane de Botton, Daniel A. Pollyea, et al.. (2015). Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. Blood. 126(23). 1306–1306. 45 indexed citations

Hansen, Erica, Cyril Quivoron, René M. Lemieux, et al.. (2014). AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. Blood. 124(21). 3734–3734. 40 indexed citations

Wang, Fang, Jeremy Travins, Yue Chen, et al.. (2014). Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model. Cancer Research. 74(19_Supplement). 3116–3116. 6 indexed citations

10.

Stein, Eytan M., Jessica K. Altman, Robert H. Collins, et al.. (2014). AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies. Blood. 124(21). 115–115. 68 indexed citations

11.

Yang, Hua, Yue Chen, Marvin B. Cohen, et al.. (2014). Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects. Blood. 124(21). 4007–4007. 2 indexed citations

12.

Fathi, Amir T., Hossein Sadrzadeh, Amy Comander, et al.. (2014). Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate. The Oncologist. 19(6). 602–607. 59 indexed citations

13.

Kernytsky, Andrew, Fang Wang, Erica Hansen, et al.. (2014). IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 125(2). 296–303. 128 indexed citations

14.

Kung, Charles, Collin Hill, Yue Chen, et al.. (2014). AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice. Blood. 124(21). 4010–4010. 1 indexed citations

15.

Quivoron, Cyril, Muriel D. David, Jeremy Travins, et al.. (2014). AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model. Blood. 124(21). 3735–3735. 17 indexed citations

16.

Kernytsky, Andrew, Fang Wang, Erica Hansen, et al.. (2014). Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition. Cancer Research. 74(19_Supplement). 2296–2296. 1 indexed citations

17.

Pollyea, Daniel A., Stéphane de Botton, Amir T. Fathi, et al.. (2014). 1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies. European Journal of Cancer. 50. 195–195. 19 indexed citations

18.

Fan, Bin, Yue Chen, Fang Wang, et al.. (2014). Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies. Blood. 124(21). 3737–3737. 6 indexed citations

19.

Chen, Yue, Fang Wang, René M. Lemieux, et al.. (2014). Abstract 1194: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human Idh1 mutant AML xenograft model. Cancer Research. 74(19_Supplement). 1194–1194. 3 indexed citations

20.

Agresta, Sam, et al.. (2013). Mutation-Selective IDH Inhibitors Mediate Histone and Dna Methylation Changes. Annals of Oncology. 24. i7–i7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact